Research & Development
Lung Cancer: Page 2
Veracyte genomic test classifies lung cancer risk in study
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
Medial EarlySign, Roche partner on lung cancer detection
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
Philips adopting proteomics results for patient management
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
Biodesix obtains Medicare coverage for lung nodule test
According to Biodesix, Nodify CDT measures seven autoantibodies associated with tumor antigens to help providers detect lung cancer across all histologies and stages.
June 6, 2022
Foundation Medicine, lung cancer groups partner in screening trial
The trial, named the "LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer" (LEADER), is the fourth study conducted through LCMC and a collaborative effort involving multiple academic study sites and pharmaceutical firms.
June 2, 2022
Labcorp to pay $19M to settle kickback, false claims lawsuit
Vaccine effectiveness against Omicron variants may change over time
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
Deepcell releases single-cell morphology data sets at AGBT general meeting
Siemens Healthineers, Unilabs ink 200-million euro agreement
Lucence promotes lung cancer research at ASCO 2022
In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.
May 31, 2022
CorePath and Cizzle partner to develop lung cancer test
The companies said they will first focus on offering the proprietary test in the U.S., where lung cancer accounts for 25% of all cancer deaths.
May 25, 2022
Biomarker data improves CT lung cancer screening's bottom line
The findings suggest a way to make CT lung cancer screening not only more useful but also economical when it comes to patient outcomes, wrote a team led by Zixuan Zhao, PhD, of Zhejiang University in Hangzhou, China.
May 23, 2022
Delfi enrolls first participants in liquid biopsy lung cancer trial
The CASCADE-LUNG study is expected to enroll 15,000 patients and aims to clinically validate Delfi's test, which detects a blood-based signal of undiagnosed lung cancer. It is a prospective, multicenter trial that will enroll participants at the time of their low-dose computed tomography (LDCT) lung cancer scans.
May 8, 2022
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
Biodesix NGS test highlighted in study
The company said the test can assay for major variant classes, which includes actionable mutations in support of comprehensive molecular testing in lung cancer.
March 31, 2022
Page 2 of 6